<DOC>
	<DOC>NCT00516373</DOC>
	<brief_summary>To determine the safety, tolerability, dose-limiting toxicity (DLT), pharmacokinetic-pharmacodynamic profile, and maximum tolerated dose (MTD) of KU-0059436 when administered orally to patients with advanced solid tumours. To further evaluate the safety and efficacy of KU-0059436 in an expanded cohort of BCRA-enriched population, primarily ovarian cancer patients.</brief_summary>
	<brief_title>A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Poly(ADP-ribose) Polymerase Inhibitors</mesh_term>
	<criteria>Confirmed malignant advanced solid tumour refractory to standard therapy or for which no suitable effective standard therapy exists. Anticancer therapy including chemotherapy, radiotherapy, endocrine therapy, immunotherapy or use of other investigational agents within the 4 weeks prior to trial entry (or a longer period depending on the defined characteristics of the agents used).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>advanced ovarian cancer</keyword>
	<keyword>BRCA 1 protein</keyword>
	<keyword>BRCA 2 protein</keyword>
	<keyword>Poly(ADP ribose)polymerases</keyword>
</DOC>